171 related articles for article (PubMed ID: 22913813)
1. Molecular mechanism of cytotoxicity induced by Hsp90-targeted Antp-TPR hybrid peptide in glioblastoma cells.
Horibe T; Torisawa A; Kohno M; Kawakami K
Mol Cancer; 2012 Aug; 11():59. PubMed ID: 22913813
[TBL] [Abstract][Full Text] [Related]
2. Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide.
Horibe T; Torisawa A; Kohno M; Kawakami K
BMC Cancer; 2014 Aug; 14():615. PubMed ID: 25159299
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic activity to acute myeloid leukemia cells by Antp-TPR hybrid peptide targeting Hsp90.
Horibe T; Kawamoto M; Kohno M; Kawakami K
J Biosci Bioeng; 2012 Jul; 114(1):96-103. PubMed ID: 22425524
[TBL] [Abstract][Full Text] [Related]
4. Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent.
Horibe T; Kohno M; Haramoto M; Ohara K; Kawakami K
J Transl Med; 2011 Jan; 9():8. PubMed ID: 21235734
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
6. Ligand discrimination by TPR domains. Relevance and selectivity of EEVD-recognition in Hsp70 x Hop x Hsp90 complexes.
Brinker A; Scheufler C; Von Der Mulbe F; Fleckenstein B; Herrmann C; Jung G; Moarefi I; Hartl FU
J Biol Chem; 2002 May; 277(22):19265-75. PubMed ID: 11877417
[TBL] [Abstract][Full Text] [Related]
7. Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin.
Yang J; Yang JM; Iannone M; Shih WJ; Lin Y; Hait WN
Cancer Res; 2001 May; 61(10):4010-6. PubMed ID: 11358819
[TBL] [Abstract][Full Text] [Related]
8. HSP27 knockdown produces synergistic induction of apoptosis by HSP90 and kinase inhibitors in glioblastoma multiforme.
Belkacemi L; Hebb MO
Anticancer Res; 2014 Sep; 34(9):4915-27. PubMed ID: 25202074
[TBL] [Abstract][Full Text] [Related]
9. Generation of a selectively cytotoxic fusion protein against p53 mutated cancers.
Kousparou CA; Yiacoumi E; Deonarain MP; Epenetos AA
BMC Cancer; 2012 Aug; 12():338. PubMed ID: 22862878
[TBL] [Abstract][Full Text] [Related]
10. In silico identification of carboxylate clamp type tetratricopeptide repeat proteins in Arabidopsis and rice as putative co-chaperones of Hsp90/Hsp70.
Prasad BD; Goel S; Krishna P
PLoS One; 2010 Sep; 5(9):e12761. PubMed ID: 20856808
[TBL] [Abstract][Full Text] [Related]
11. The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells.
Schaefer S; Svenstrup TH; Guerra B
PLoS One; 2017; 12(5):e0177706. PubMed ID: 28542269
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
[TBL] [Abstract][Full Text] [Related]
13. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
[TBL] [Abstract][Full Text] [Related]
14. The architecture of functional modules in the Hsp90 co-chaperone Sti1/Hop.
Schmid AB; Lagleder S; Gräwert MA; Röhl A; Hagn F; Wandinger SK; Cox MB; Demmer O; Richter K; Groll M; Kessler H; Buchner J
EMBO J; 2012 Mar; 31(6):1506-17. PubMed ID: 22227520
[TBL] [Abstract][Full Text] [Related]
15. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Zismanov V; Drucker L; Gottfried M
Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer.
Ruckova E; Muller P; Nenutil R; Vojtesek B
Cell Mol Biol Lett; 2012 Sep; 17(3):446-58. PubMed ID: 22669480
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta activity.
Sumanasekera WK; Tien ES; Davis JW; Turpey R; Perdew GH; Vanden Heuvel JP
Biochemistry; 2003 Sep; 42(36):10726-35. PubMed ID: 12962497
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW
Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]